Geng Y, Mei Y, Xi Y, et al. - Among patients who received EGFR (epidermal growth factor receptor) tyrosine kinase inhibitors (EGFR-TKIs) targeted therapy for lung adenocarcinoma (LAC), this inquiry was performed to investigate the predictive ability of pretreatment circulating bilirubin for progression-free survival (PFS). There were 180 patients with LAC who had undergone EGFR-TKIs targeted therapy included and retrospectively reviewed. In Kaplan–Meier survival curves and Log rank tests, a shorter median PFS was seen in patients with lower bilirubin levels vs those with higher bilirubin levels. In multivariate analysis, pretreatment bilirubin was shown to be an independent prognostic factor. Overall, findings corroborated that in LAC patients who had received EGFR-TKIs targeted therapy, the prognosis can be predicted by bilirubin.